EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses.

ABSTRACT:

Background

High-grade gliomas including glioblastoma (GBM) and diffuse midline gliomas (DMG) represent the most lethal and aggressive brain cancers where current treatment modalities offer limited efficacy. Chimeric antigen receptor (CAR) T cell therapies have emerged as a promising strategy, boasting tumor-specific targeting and the unique ability to penetrate the blood-brain barrier. However, the effective clinical application hinges on the optimal choice of antigen, with a limited number, currently under investigation.

Methods

We employed cell surface proteomic analysis of primary human high-grade glioma samples from both adult and pediatric patients. This led to the identification of Ephrin type-A receptor 3 (EphA3) as a prevalently expressed target. We engineered a seco

SUBMITTER: Lertsumitkul L 

PROVIDER: S-EPMC11308882 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature